ArticleInsights into imaging2026
European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRI has a central role in the diagnosis and management of prostate cancer, including active surveillance (AS) of low- and favourable intermediate-risk cancer. Robust evidence supports its use to guide biopsies and stratify the risk of progression at the inclusion stage. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) criteria provide the foundation for standardised assessment on serial imaging during AS. Despite potential reductions in the number of unnecessary follow-up biopsies, uncertainty about the degree to which follow-up strategies can be defined by MRI leads to variation in international guidelines and their implementation. Here, the European Society of Urogenital Radiology (ESUR)-Prostate MRI Working Group reviews the evidence for the use of MRI in AS and provides practical guidance on its use. Additional research is needed to personalise AS strategies by integrating patient-specific factors, including family history and ethnicity, as well as emerging biomarkers such as genomic profiling and technological innovations like artificial intelligence. CRITICAL RELEVANCE STATEMENT: MRI is an integral part of AS, and initiatives to standardise image acquisition and reporting are underway. Further research is needed to better define MRI's role during follow-up and to personalise AS, which could help achieve better harmonisation among international guidelines. The European Society of Urogenital Radiology (ESUR) prostate working group provides suggestions for practical implementation. Active surveillance is a safe and effective management strategy for indolent prostate cancer. It avoids complications associated with surgery and radiation treatment. MRI has a central role in selecting which patients will benefit most from active surveillance and helping choose the most appropriate follow-up strategy. Acquiring standardised images and using reporting systems like PRECISE improves prostate cancer assessment and may help reduce the number of unnecessary biopsies. KEY POINTS: MRI plays a central role during active surveillance, but its implementation varies widely across centres. This ESUR position statement offers practical guidance on MRI acquisition, reporting, and interpretation tailored to active surveillance. Use of MRI-including the PRECISE score for active surveillance and the PI-QUAL score for image quality-can improve consistency and accuracy in monitoring prostate cancer over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.